| Host: |
E.coli |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Formulation: |
Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: |
< 1 EU/Mu g of the protein by LAL method. |
| Immunogen Region: |
Phe29-Pro243＆Arg21-Lys229 |
| Immunogen: |
Recombinant Human IL-27/IL-27A&IL-27B Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Phe29-Pro243＆Arg21-Lys229 ) of IL-27A (Accession #NP_663634.2) fused with a His tag at the N-terminus and IL-2 |
| Immunogen Sequence: |
CGPGRVVGSRRRPPRKLVPL AYKQFSPNVPEKTLGASGRY EGKIARSSERFKELTPNYNP DIIFKDEENTGADRLMTQRC KDRLNSLAISVMNQWPGVKL RVTEGWDEDGHHSEESLHYE GRAVDITTSDRDRNKYGLLA RLAVEAGFDWVYYESKAHVH CSVKSEHSAAAKTGG |
| Background | IL-27 protein is a member of the IL-6 superfamily, which is expressed on monocytes, endothelial cells, and dendritic cells. IL-27 protein is also referred to as the IL-12 p35-related protein, p28, is one subunit of a heterodimeric cytokine complex, and associates with another subunit EBI3, and IL-12 p40-related protein (IL-27B). IL-27 protein is an early product of activated antigen-presenting cells and drives the rapid clonal expansion of naive CD4 (+) T cells and plays a role in the early regulation of Th1 cells initiation which drives efficient adaptive immune response. IL-27 protein has an antiproliferative activity on melanomas through WSX-1/STAT1 signaling. Thus, IL-27 protein may be an attractive candidate as an antitumor agent applicable to cancer immunotherapy. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
